CDP-Choline (Citicoline) for Stroke Recovery

Verdict: Does not improve stroke recovery

High-quality randomized trials and a Cochrane review show that CDP-choline (citicoline) does not improve survival, disability, or functional recovery after an ischemic stroke. The current evidence places it in the counter-evidence category, not as a useful recovery aid.

D 🔴 D Counter-Evidence Counter-Evidence

🔬Why this grade7-layer evidence engine

The grade rests on the strongest available trials returning null results. The large, double-blind ICTUS trial (PMID 22691567; n=2,298) found global recovery at 90 days no better than placebo (OR 1.03, 95% CI 0.86-1.25; p=0.364). A 2020 Cochrane review (PMID 32860632; 10 RCTs, n=4,281) likewise found little to no effect on mortality (RR 0.94) or disability (RR 1.11), rated low-certainty, and a separate 2022 RCT (PMID 35639720) showed no benefit on any outcome.

An earlier 2016 meta-analysis (PMID 27234918) had suggested benefit (OR 1.56, 95% CI 1.12-2.16), but it was dominated by smaller, older studies and has since been superseded by the much larger ICTUS trial and the Cochrane review. Cochrane also noted that 6 of the 10 pooled trials were industry-sponsored with inadequate adverse-event reporting, which further weakens that early positive signal.

Regulators and major clinical bodies offer no support for this use. The US FDA has not approved any stroke claim for citicoline and has cited CDP-choline products marketed for stroke as misbranded, while EFSA rejected related health claims for insufficient evidence. Leading clinics (NIH ODS, Mayo, Cleveland Clinic, Harvard Health) do not endorse it for stroke recovery, where multidisciplinary rehabilitation remains the established standard of care.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.34
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
D · Counter-Evidence
Confidence
84%
Highly consistent evidence
Evidence level
E2
Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.20
L3 MechanismPlausibility
0.25
L11 AI re-checkIndependent read
0.30
L1 ExamineGlobal benchmark
0.50
L5 Clinical bodiesAuthoritative stance
0.55
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.34
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Citicoline for treating people with acute ischemic stroke
PMID: 32860632 2020 系統性回顧 n = 4,281
Finding: Little to no difference vs control for mortality (RR 0.94, 95% CI 0.83-1.07) or disability (RR 1.11, 95% CI 0.97-1.26); low-certainty evidence.
🟢 High quality Government Effect size: RR 1.11 (95% CI 0.97-1.26) for disability/dependence
View on PubMed
Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)
PMID: 22691567 2012 RCT (double-blind) n = 2,298
Finding: NULL result: global recovery similar in both arms (OR 1.03, 95% CI 0.86-1.25; p=0.364); citicoline not efficacious for moderate-to-severe acute ischaemic stroke.
🟢 High quality ⚠️ Industry-funded Effect size: OR 1.03 (95% CI 0.86-1.25)
View on PubMed
Citicoline for Acute Ischemic Stroke: A Systematic Review and Formal Meta-analysis of Randomized, Double-Blind, and Placebo-Controlled Trials
PMID: 27234918 2016 統合分析
Finding: Higher independence rate with citicoline (random-effects OR 1.56, 95% CI 1.12-2.16); but on top of rtPA the benefit is limited.
Effect size: OR 1.56 (95% CI 1.12-2.16, random effects)
View on PubMed
Citicoline in acute ischemic stroke: A randomized controlled trial
PMID: 35639720 2022 RCT (double-blind)
Finding: No significant difference vs placebo on any primary/secondary outcome (ORs 0.96/0.92/0.87, all NS; infarct volume p=0.483).
Effect size: OR 0.92 for mRS 0-2 (not significant)
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
L4d TW TFDA / 衛福部
Cautious
胞磷膽鹼 (Citicoline) 在台灣以西藥許可證列管,屬腦循環代謝改善劑類處方藥 (如尼可林 Nicholin 胞磷膽鹼鈉注射液),適應症為急性頭部外傷及腦部手術後之意識障礙;須憑醫師處方使用。 source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-stroke-recovery-INT-cdp-choline-001 繁體中文版 →